Pipeline

A Patient Driven Multi-Stage Pipeline

Candidate Target Indications Development Phase Partner
Preclinical Phase 1 Phase 2 Phase 3

CAP-1002

(allogeneic CDCs)

Duchenne muscular dystrophy

Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress

Nippon Shinyaku
(U.S. and Japan rights)

Exosome-Based Vaccine

(Multivalent design)

Infectious diseases

(SARS-CoV-2)

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

Engineered Exosomes

(RNA, protein and small molecule delivery)

Evaluating

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

CAP-2003

(allogeneic CDC-exosomes)

Duchenne muscular dystrophy

Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started

Cell Therapy

Exosome Platform